192
Participants
Start Date
May 3, 2021
Primary Completion Date
October 1, 2022
Study Completion Date
December 6, 2022
ChulaCov19 vaccine
SARS-Cov2 Wild-type S-spike mRNA/ lipid nanoparticle (LNP) vaccine
Placebo
Saline
Chula Vaccine Research Center (ChulaCRC) Faculty of Medicine Chulalongkorn University, Bangkok
Center of Excellence for Vaccine Trial (Vaccine Trial Centre), Faculty of Tropical Medicine Mahidol University, Bangkok
Chula Vaccine Research Center (ChulaVRC), Bangkok, Thailand
UNKNOWN
Center of Excellence in Vaccine Research and Development, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
UNKNOWN
Chula Clinical Research Center (Chula CRC), King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
UNKNOWN
King Chulalongkorn Memorial Hospital (KCMH), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
UNKNOWN
Mahidol University
OTHER
National Vaccine Institute, Thailand
OTHER
Chulalongkorn University
OTHER